I was trying to remember why Rothchild & Co was brought in so I decided to check (brilliant eh). Hope they have their assignment complete and in place and ready to trigger when BoM possibly succeeds and I hope they have considered the Zenith side.

RESVERLOGIX INTENDS TO PURSUE U.S. LISTING

July 31, 2018

CALGARY, Alberta, July 31, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly, if necessary in order to comply with stock exchange minimum share price requirements and in connection with any future equity financing associated therewith, the Company intends to request shareholder approval for a consolidation of the Company’s common shares at an annual and special meeting of shareholders of the Company (the “Meeting”) to be held on September 12, 2018. If approved by shareholders, the Board will have the discretion to proceed with the share consolidation for a period of 12 months following the Meeting. The Company’s common shares and warrants would continue to be listed on the Toronto Stock Exchange.

Resverlogix has engaged Rothschild & Co. as its financial advisor to evaluate a potential U.S. listing. 

Listing will be subject to the Company satisfying all applicable stock exchange and U.S. securities law requirements. As in such cases, there is no assurance that the Company will be able to do so.

Further information regarding the Meeting and the share consolidation will be available in a notice of meeting and management information circular to be filed and mailed to all shareholders of the Company in advance of the Meeting.

“We are initiating preparation for a U.S. listing in light of several anticipated developments in the Company.  We anticipate the completion of the BETonMACE trial around the end of 2018 and, soon after, the announcement of the results of our primary endpoint of the reduction of major adverse cardiac events (MACE) in patients with diabetes and other prespecified endpoints such as renal and cognitive function. We have commenced the preparation process for a U.S. listing so that we are properly positioned to execute a U.S. listing, subject to market conditions,” stated Donald McCaffrey, President and CEO of Resverlogix.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low levels of high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations
Email:ir@resverlogix.com
Phone: 403-254-9252